Company Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States.
The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States.
Its pipeline products include biosimilars of Humira, Avastin, and Lucentis.
The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar.
Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences.
The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012.
Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
| Country | United States |
| IPO Date | Nov 6, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 235 |
| CEO | Dennis M. Lanfear |
Contact Details
Address: 333 Twin Dolphin Drive Redwood City, California United States | |
| Website | https://www.coherus.com |
Stock Details
| Ticker Symbol | CHRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001512762 |
| CUSIP Number | 19249H103 |
| ISIN Number | US19249H1032 |
| Employer ID | 27-3615821 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dennis M. Lanfear | Chairman, President & Chief Executive Officer |
| Bryan J. McMichael | Former Interim Chief Financial Officer, Principal Financial and Acc. Off., SVice President-Acc. & Corporate Controller |
| Andy Rittenberg | Executive Vice President of General Counsel |
| Dr. Theresa M. Lavallee Ph.D. | Chief Development Officer & Chairman of Scientific Advisory Board |
| Jodi Sievers | Vice President of Investor Relations & Corporate Communications |
| Michael Chen | Senior Vice President of Commercial Analytics & Trade |
| Paul Reider | Chief Commercial Officer |
| Rebecca Sunshine | Chief Human Resources Officer |
| Richard L. Hameister | Chief Technical Officer |
| Scott Saywell | Executive Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 04, 2024 | 8-K | Current Report |
| Dec 04, 2024 | DEFA14A | Filing |
| Dec 04, 2024 | DEFA14A | Filing |
| Dec 03, 2024 | DEFA14A | Filing |
| Dec 03, 2024 | DEFA14A | Filing |
| Dec 03, 2024 | 8-K | Current Report |
| Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 8-K | Current Report |